The present invention consists of an ophthalmic laser probe system which aims to simplify transscleral cyclophotocoagulation and pulsed transscleral laser therapy for glaucoma by the use of a scanning probe placed on the limbus or perilimbal area with the use of an optical switching mechanism and multiple fibers. The system replaces the sweeping or repositioning motion of existing probes by sequential shots through multiple fibers, allowing the probe to be held in a fixed position to cover at least the treatment of one quadrant of the eye.
Fiber optic laser probes are commonly used to transmit laser energy for medical applications. Transscleral cyclophotocoagulation and pulsed transscleral laser therapy involve the placement of a fiber optic probe over the surface of the eye on the limbus or perilimbal area, with the fiber tip approximately 0-3 mm away from the limbus in order to transsclerally emit laser radiation towards the ciliary processes.
“Transscleral cyclophotocoagulation” aims to destroy some of the ciliary processes in order to reduce intraocular pressure by applying continuous wave laser energy to a series of selected points (Gaasterland D.,et al, “Initial Experience with a New Method of Laser Transscleral Cyclophotocoagulation for Ciliary Ablation in Severe Glaucoma”, Trans Am Ophthalmol Soc 90:225-246, 1992) whereas “pulsed transscleral laser therapy” uses a pulsed laser with short on/off time cycles, with the probe moved in a sweeping motions in the upper and lower perilimbal semi-circles (Williams A. L., et al, “Clinical Efficacy and Safety Profile of Micropulse Transscleral Cyclophotocoagulation in Refractory Glaucoma”, J Glaucoma 2018;27: 445-449).
Existing probes are either moved in steps or in a sweeping motion to cover the necessary portion of the treatment area. The proximal end of the probe is attached to an ophthalmic photocoagulation laser which generates a laser beam while the distal end is placed on the perilimbal area. Laser shots have either a destructive (continuous wave) or non-destructive (pulsed, tissue-sparing) effect on the ciliary processes transsclerally for the treatment of glaucoma.
Existing probe designs have a shaped tip containing a single laser fiber (e.g. U.S. Pat. No. 5,372,595 to Gaasterland, et al, U.S. Pat. No. 8,945,103 to Chew, et al, U.S. Pat. No. 9,700,461 to Buzawa, et al), or a single laser fiber with an additional illumination fiber (e.g. U.S. Pat. No. 9,629,749 to Vold, et al) as well as more basic rounded fiber tips without surrounding footplate. The concept of a replaceable tip has also been considered (e.g. U.S. Pat. No. 10,758,118 to Chen, et al). While continuous wave transscleral laser cyclophotocoagulation which destroys some of the ciliary processes has been practiced for decades, tissue-sparing transscleral laser therapy with short duration laser pulses has become common practice in recent years. The outcome of both treatment modalities is dependent on the surgeon's manual skills, with the probe tip getting caught on or damaging the conjunctiva during repositioning or sweeping motion presenting an occasional hurdle.
An ophthalmic transscleral laser probe is an instrument whose proximal end attaches to an ophthalmic photocoagulating laser via a connector and its distal end is placed in contact with the perilimbal area of the eyeball for the purpose of transferring laser energy to treat ophthalmic tissue. The most common applications of the transscleral laser are transscleral cyclophotocoagulation and pulsed transscleral laser therapy, i.e. the destructive or non-destructive heating of the ciliary processes with laser light. Transscleral cyclophotocoagulation typically shoots 10-22 laser shots with the probe placed at distinct intervals, whereas pulsed transscleral laser therapy use a sweeping motion over the lower and upper perilimbal areas, leaving the nasal and temporal sections untreated.
Prior art transscleral probes have a single laser firing fiber (and sometimes an illumination fiber) but lack the scanning ability unique to the invention. Prior art transscleral laser probes have a single connector 14, a single optical fiber 12, a protective tubing 10 to mechanically protect the fiber, a handpiece 16 for the surgeon to hold the probe tip pressed onto the eyeball in the perilimbal region. Some models have multiple fibers 12, with one fiber to carry the laser beam and the others to carry an illumination component.
An optical switching mechanism 22 (prior art) is a commercially available device with one input socket 30 and several output sockets 28. Laser energy entering the switch via the input socket 30 is diverted to one of the output sockets 28. Electronic control of the device allows switching from one output socket to another.
The apparatus in the present invention has a similar structure as prior art commercially available transscleral laser probes, but contains multiple connectors 14, multiple laser fibers 12 and a multiple fiber holding piece 18 at the tip, with all fibers 12 attached to an optical switching mechanism 22 through several connectors 14. The optical switching mechanism 22 is itself connected to the output 20 of the laser unit 26 via a fiber optic cable 24. Laser power from the laser unit 26 is sequentially distributed to the output sockets 28 and to the probe through the connectors 14 and the optical fibers 12. The optical switching mechanism 22 allows electronic control of parameters such as the selection of output socket 28 and the duration of the laser shot at each socket.
The novelty of the invention is its capability to shoot several laser spots sequentially on the perilimbal area 34 in a pattern 32 as shown in
The surgeon will shoot a treatment pattern 32, followed by a relocation of the probe tip 18 to the next quadrant or semi-circle treatment location. This will be followed by another treatment sequence, with the process repeated until completion of the treatment for the whole eye.
The preferred embodiment of the invention is represented in
A second embodiment with identical features except for a tip 36 with protruding fibers, with rounded, spherical, flat or otherwise shaped ends is shown in
A third embodiment has a semi-circular tip (
A fourth embodiment has two semi-circular tips allowing to treat the upper and lower semi-circles 40, leaving out the nasal and temporal sections (
A fifth embodiment has a 360 degree tip covering the whole perilimbal area 42, with the selection of the treatment area defined by the optical switching system (
Publications
Gaasterland D, Pollack I., “Initial Experience with a New Method of Laser Transscleral Cyclophotocoagulation for Ciliary Ablation in Severe Glaucoma”, Trans Am Ophthalmol Soc 90:225-246, 1992
Williams A L, Moster M R, Rahmatnejad K, Resende A F, Horan T, Reynolds M, Yung E, Abramowitz B, Kuchar S, Waisbourd M, “Clinical Efficacy and Safety Profile of Micropulse Transscleral Cyclophotocoagula-tion in Refractory Glaucoma”, J Glaucoma 2018;27: 445-449
Patents
U.S. Pat. No. 5,372,595 Gaasterland, et al, “Contact probe for laser cyclophotocoagulation”, Dec. 13, 1994
U.S. Pat. No. 8,945,103 Chew, et al, “Contact probe for the delivery of laser energy”, Feb. 3, 2015
U.S. Pat. No. 9,700,461 Buzawa, et al, “Convex contact probe for the delivery of laser energy”, Jul. 11, 2017
U.S. Pat. No. 9,629,749 Vold, et al, “Illuminated treatment probe for delivering laser energy”, Apr. 25, 2017
U.S. Pat. No. 10,758,118 Chen, et al, “Handheld ophthalmic laser system with replaceable contact tips and treatment guide”, Sep. 1, 2020
Number | Date | Country | |
---|---|---|---|
63265319 | Dec 2021 | US |